---
title: "IONS: H1 2026 revenue up 27% YoY, driven by new product launches and strong commercial execution"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294206672.md"
description: "Strong H1 2026 revenue growth driven by successful launches of TRYNGOLZA and DAWNZERA, with commercial revenue up 27% YoY and robust cash reserves of $2.1B. 2026 guidance targets $875–$900M in revenue and continued investment in pipeline expansion.Original document: Ionis Pharmaceuticals, Inc. [IONS] Slides Release — Jul. 29 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-29T12:18:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294206672.md)
  - [en](https://longbridge.com/en/news/294206672.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294206672.md)
generator: "portal-rs"
---

# IONS: H1 2026 revenue up 27% YoY, driven by new product launches and strong commercial execution

Strong H1 2026 revenue growth driven by successful launches of TRYNGOLZA and DAWNZERA, with commercial revenue up 27% YoY and robust cash reserves of $2.1B. 2026 guidance targets $875–$900M in revenue and continued investment in pipeline expansion.

Original document: Ionis Pharmaceuticals, Inc. \[IONS\] Slides Release — Jul. 29 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)

## Related News & Research

- [Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/296455358.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [BEWI: Q2 2026 delivered double-digit sales and EBITDA growth, with strong performance across all segments](https://longbridge.com/en/news/296303987.md)
- [DE: 3Q 2026 saw sales and profit growth, but FY 2026 guidance signals industry headwinds](https://longbridge.com/en/news/296475895.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**